These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 23740572)

  • 21. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era.
    Launay D; Sitbon O; Hachulla E; Mouthon L; Gressin V; Rottat L; Clerson P; Cordier JF; Simonneau G; Humbert M
    Ann Rheum Dis; 2013 Dec; 72(12):1940-6. PubMed ID: 23178295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.
    Lammi MR; Saketkoo LA; Gordon JK; Lauto P; Fagan K; Steen VD;
    Respirology; 2017 Oct; 22(7):1386-1392. PubMed ID: 28500695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival after lung transplantation in systemic sclerosis. A systematic review.
    Khan IY; Singer LG; de Perrot M; Granton JT; Keshavjee S; Chau C; Kron A; Johnson SR
    Respir Med; 2013 Dec; 107(12):2081-7. PubMed ID: 24113572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.
    Mihai C; Antic M; Dobrota R; Bonderman D; Chadha-Boreham H; Coghlan JG; Denton CP; Doelberg M; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Rosenberg DM; Seibold JR; Vonk MC; Distler O
    Ann Rheum Dis; 2018 Jan; 77(1):128-132. PubMed ID: 29061853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.
    Campo A; Mathai SC; Le Pavec J; Zaiman AL; Hummers LK; Boyce D; Housten T; Champion HC; Lechtzin N; Wigley FM; Girgis RE; Hassoun PM
    Am J Respir Crit Care Med; 2010 Jul; 182(2):252-60. PubMed ID: 20339143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
    Young A; Vummidi D; Visovatti S; Homer K; Wilhalme H; White ES; Flaherty K; McLaughlin V; Khanna D
    Arthritis Rheumatol; 2019 Aug; 71(8):1339-1349. PubMed ID: 30762947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
    Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
    Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.
    Launay D; Montani D; Hassoun PM; Cottin V; Le Pavec J; Clerson P; Sitbon O; Jaïs X; Savale L; Weatherald J; Sobanski V; Mathai SC; Shafiq M; Cordier JF; Hachulla E; Simonneau G; Humbert M
    PLoS One; 2018; 13(5):e0197112. PubMed ID: 29763468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
    Hinchcliff M; Fischer A; Schiopu E; Steen VD;
    J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes.
    Brown Z; Proudman S; Morrisroe K; Stevens W; Hansen D; Nikpour M
    Semin Arthritis Rheum; 2021 Jun; 51(3):495-512. PubMed ID: 33857705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.
    Hsu VM; Chung L; Hummers LK; Shah A; Simms R; Bolster M; Hant FN; Silver RM; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Saketkoo LA; Salazar CR; Steen VD
    J Rheumatol; 2019 Feb; 46(2):176-183. PubMed ID: 30275260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Kowal-Bielecka O; Avouac J; Pittrow D; Huscher D; Behrens F; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE; Distler O;
    J Rheumatol; 2011 Nov; 38(11):2419-27. PubMed ID: 21965635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study.
    Gadre A; Ghattas C; Han X; Wang X; Minai O; Highland KB
    Lung; 2017 Oct; 195(5):529-536. PubMed ID: 28646245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult.
    Hesselstrand R; Wildt M; Ekmehag B; Wuttge DM; Scheja A
    Scand J Rheumatol; 2011 Mar; 40(2):127-32. PubMed ID: 20858146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.